Literature DB >> 18456374

DNA fusion vaccines incorporating IL-23 or RANTES for use in immunization against influenza.

J Williman1, S Young, G Buchan, L Slobbe, M Wilson, P Pang, J Austyn, S Preston, M Baird.   

Abstract

The incorporation of RANTES or IL-23 into DNA vaccines may improve their immunogenicity by the recruitment and activation of dendritic cells. This may also select for a TH1 response counteracting the TH2 response which can predominate when a DNA vaccine is delivered by gene gun. We have immunized mice with various DNA constructs encoding APR/8/34 influenza virus hemagglutinin (HA), either fused to or separate from, IL-23 or RANTES using a gene gun. Those immunized with IL-23/HA fusion constructs and challenged with influenza 27 weeks post-vaccination, tended to have cleared more virus than those vaccinated with HA DNA. Mice immunized with the RANTES/HA fusion construct produced a mixed TH1/TH2 response whereas in HA-vaccinated mice, a TH2 response predominated. Immunization with a plasmid in which HA and RANTES were under the control of separate promoters, failed to generate a mixed TH1/TH2 response suggesting that enhanced antigen uptake via RANTES receptors may contribute to the mixed immune response generated to the fusion construct. Overall these findings provide further evidence that Type 1 cytokines or chemokines, fused to antigen in a DNA vaccine, can influence the nature and the longevity of the immune response and ultimately, its protective capacity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456374     DOI: 10.1016/j.vaccine.2008.03.084

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Th17 cytokines and vaccine-induced immunity.

Authors:  Yinyao Lin; Samantha R Slight; Shabaana A Khader
Journal:  Semin Immunopathol       Date:  2010-01-30       Impact factor: 9.623

Review 2.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

3.  Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.

Authors:  Maowei Wang; Yan Yue; Chunsheng Dong; Xiaoyun Li; Wei Xu; Sidong Xiong
Journal:  Clin Vaccine Immunol       Date:  2013-09-11

4.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

5.  Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.

Authors:  Yan Yue; Wei Xu; Sidong Xiong
Journal:  DNA Cell Biol       Date:  2011-10-11       Impact factor: 3.311

6.  IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge.

Authors:  K Kai McKinstry; Tara M Strutt; Amanda Buck; Jonathan D Curtis; John P Dibble; Gail Huston; Michael Tighe; Hiromasa Hamada; Stewart Sell; Richard W Dutton; Susan L Swain
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

7.  Intranasal administration of poly-gamma glutamate induced antiviral activity and protective immune responses against H1N1 influenza A virus infection.

Authors:  Eun-Ha Kim; Young-Ki Choi; Chul-Joong Kim; Moon-Hee Sung; Haryoung Poo
Journal:  Virol J       Date:  2015-10-06       Impact factor: 4.099

8.  Tuberculosis vaccine development: Shifting focus amid increasing development challenges.

Authors:  A J Graves; D A Hokey
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

9.  Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection.

Authors:  Asher Maroof; Yvonne M Yorgensen; Yufeng Li; Jay T Evans
Journal:  PLoS Pathog       Date:  2014-01-23       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.